Sign in
Taking people in United StatesPhase 1

Testing clonidine, hydrochlorothiazide, or placebo for inflammation in obesity

Tests clonidine against a blood pressure pill and placebo in adults with obesity.

Key facts

Who runs it
University of Kansas Medical Center
Where
Kansas City, United StatesSee the site
Trial code
Registry title
Mitigating the Pro-inflammatory Phenotype of Obesity
Status
Recruiting
Phase
Phase 1
People taking part
60 people, planned
Started
1 Jul 2021
Expected to end
1 Aug 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Hydrochlorothiazide 12.5Mg Tab
  • Clonidine Pill
  • Placebo
Record updated
5 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity, high blood pressure and raised insulin resistance. It tests 4 weeks of clonidine, a diuretic or a placebo.

Age
18 to 79 years
Sex
Men and women can join.
Disease stage
Obesity (BMI > 30 m/kg2), blood pressure > 130/80, raised insulin resistance (HOMA-IR > 2.5), waist > 102 cm (3 ft 4 in) (men) or > 88 cm (35 in) (women). Fasting glucose < 126 mg/dL (7 mmol/L), fasting triglycerides < 250 mg/dL (2.8 mmol/L), HbA1c < 6.5% (48 mmol/mol).
Earlier treatment
People currently taking clonidine, beta-blockers or hypertension medication cannot join.
Biomarker or test result
HOMA-IR > 2.5; fasting glucose < 126 mg/dL (7 mmol/L); fasting triglycerides < 250 mg/dL (2.8 mmol/L); HbA1c < 6.5% (48 mmol/mol).

Main reasons for not taking part

  • Current use of clonidine or beta-blockers
  • Smoking now or in the past 3 months
  • Currently taking hypertension medication
  • History of heart disease, such as heart attack, stroke or heart failure
  • History of neurological disorders or of a transplant

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Male or Female, age 18-79
  • Obese: BMI > 30 m/kg2
  • Hypertensive: blood pressure >130/80
  • Elevated insulin resistance (HOMA-IR > 2.5)
  • Waist circ: >102 cm (men) and >88 cm (women)
  • Fasting glucose < 126 mg/dL
  • Fasting triglycerides < 250 mg/dL
  • HbA1c < 6.5%
  • Willing to visit research lab (Fairway CTSU)
  • Willing to undergo a blood draw
  • Able to provide written informed consent

Who cannot take part

  • Currently taking hypertension medication
  • Current smoker or History of smoking in the past 3 months
  • History of heart disease (e.g., myocardial infarction, stent, byass, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)
  • History of neurological disorders
  • History of transplant
  • Hyperlipidemia: Fasting triglycerides > 250 mg/dL
  • Current use of clonidine or beta-blockers
  • Actively participating in other studies, except for a registry study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Where in United States

  • University of Kansas Medical CenterKansas City, United StatesContact: Seth W. W HolwerdaTaking people

About the trial

What the trial wants to find out

The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6).

Read full original descriptionShow less

Our study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.

The 3 groups in the trial

  • PlaceboPlacebo, for comparison

    KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of placebo to the research coordinator to give to the research participant. The placebo is an inert substance with no intended medical value and is used as a negative control for comparison with the study drug. Participants will receive a Placebo Pill; has no active ingredients but is made to look like the study drug.

  • ClonidineTreatment being tested

    KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of clonidine to the research coordinator to give to the research participant. Planned use in this study 1. Condition/disease indication(s): Vascular function and blood flow 2. Subject population: Hypertension 3. Dose(s): 0.1 mg (oral) 4. Administration: Oral 5. Dosing regimen: 0.1 mg twice daily by mouth

    Treatment: Clonidine Pill

  • Hydrochlorothiazide (HCTZ)Treatment being tested

    KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of Hydrochlorothiazide to the research coordinator to give to the research participant. Planned use in this study 1. Condition/disease indication(s): Hypertension 2. Subject population: Hypertension 3. Dose(s): 25 mg/day 4. Administration: Oral 5. Dosing regimen: 12.5 mg twice per day

    Treatment: Hydrochlorothiazide 12.5Mg Tab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Mitigating the Pro-inflammatory Phenotype of Obesity
Plain-language title
Testing clonidine, hydrochlorothiazide, or placebo for inflammation in obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04934228, who can take part
Record updated
5 June 2025